Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
NCT Number: NCT03670862
Prediction model for the Recanalization OuTcome Evaluation of ischemic stroke using multimodal CT (PROTECT) study was a multicenter prospective observational study that recruited patients from 13 centers located in 10 provinces across China. The study was to assess the effects of novel imaging biomarkers/ imaging patterns based on multimodel CT for patients selection and outcome prediction in acute ischemic stroke.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 100853, China
Patients Patients with cerebral ischemia symptoms of anterior circulation or posterior circulation onset in 24 hours were included. A neurological evaluation (Modified Rankin Scale and NIHSS); physical examination, including measurement of weight (kg) and vital signs (supine systolic and diastolic blood pressure); time from symptom onset to enrollment were recorded.
Imaging protocols:
CT scan protocols: Non-contrast computed tomography(NCCT) , computed tomography angiography(CTA), computed tomography perfusion(CTP)
Contrast agent:
CTA: Omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s
CTP: Omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s
Imaging evaluation:
CTA was reviewed and stenosis or occlusive lesions were identified. Parameter maps including cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the residue function derived from CTP were processed by the software Rapid to quantitatively assess infarct core volume and mismatch.
Multiphase CTA was extracted from CTP to evaluate the collateral circulation.
Treatment:
Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy, and conventional treatment including neuroprotection, anti-platelet, and statin according to the guideline.
Follow up:
Modified Rankin Scale(mRS) was obtained at 90 days after symptom onset. An imaging follow-up was also recommended within 30 days after symptom onset.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
Time frame: 90 days after symptom onset
Assessed by modified Rankin Scale with scores ranging from 0 (no symptoms) to 6 (death)
Time frame: within 30 days after symptom onset
Finding the predictive value of novel imaging biomarkers/ imaging patterns on final infarction volume
Time frame: within 7 days after symptom onset
Symptomatic hemorrhagic transformation after acute ischemic stroke
Chinese PLA General Hospital
Other
Acronym: PROTECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT05559398
Brain Diseases, Cardiovascular Diseases
Bron, France
View Trial DetailsNCT04042584
Brain Diseases, Cardiovascular Diseases
Bordeaux, France
View Trial DetailsNCT04000971
Behavior, Brain Diseases
Birmingham, Alabama, United States
View Trial Details